🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
Organization MAKSCIENTIFIC, LLCLocation BURLINGTON, UNITED STATESPosted 1 Jun 2023Deadline 31 Aug 2025 ⚠️
NIHUS FederalResearch GrantFY20252-AG2-arachidonoyl-glycerol2-arachidonoyl-sn-glycerol2-arachidonoylglycerol2-arachidonyl-glycerol2-arachidonylglycerolABC20ABCB1ABCB1 geneAbstinenceAddressAffinityAgonistAnalgesic ManagementAnochlesiaAssayBehavioralBehavioral AssayBioassayBioavailabilityBiochemicalBiological AssayBiological AvailabilityBlood PlasmaBrainBrain Nervous SystemBusinessesCB1CB1 ReceptorCB1RCNR1 geneCannabinoid Receptor CB1CannabisCatalepsyCesametClinical TrialsCognitive DiscriminationCommon Rat StrainsDependenceDevelopmentDiscriminationDoseDrug DesignDrug KineticsDrug Synthesis and ChemistryDrugsEncephalonEndocannabinoidsEndogenous CannabinoidsEnzyme GeneEnzyme InhibitionEnzymesEvaluationExclusionExhibitsFAAH proteinFDA approvedGP170GenerationsGlycerol Monoester HydrolasesGlycerol-ester acylhydrolaseGoalsHepaticHumanHypothermiaIn VitroIn vivo analysisIncidenceIsoenzymesIsozymesLeadLigandsMAGL inhibitorMDR-1MDR1MDR1 ProteinMarijuanaMediatingMedicalMedicationMedication ManagementMetabolicMicrosomesMissionModern ManMonkeysMonoacylglycerol LipasesMonoglyceride EsterasesMonoglyceride HydrolaseMonoglyceride LipasesMultidrug Resistance 1Multidrug Resistance Gene-1Multidrug Resistance Gene-1sMultidrug Resistance ProteinsMultidrug Resistant ProteinsN arachidonoyl 2 hydroxyethylamideN-arachidonoylethanolamineNIDANabiloneNational Institute of Drug AbuseNational Institute on Drug AbuseOralP-GPP-GlycoproteinP-Glycoprotein 1 GenePGY-1 ProteinPGY1ParentsPb elementPharmaceutical AgentPharmaceutical PreparationsPharmaceuticalsPharmacokineticsPharmacologic ManagementPharmacologic SubstancePharmacological SubstancePhasePhase 2 Clinical TrialsPhase II Clinical TrialsPhysiologicPhysiologic AvailabilityPhysiologicalPlasmaPlasma SerumPropertyPublic HealthRatRats MammalsRattusRecreationReportingResearchReticuloendothelial System, Serum, PlasmaRodentRodentiaRodents MammalsScienceSelection CriteriaSelf AdministeredSelf AdministrationSmokeSolubilityStimulusSymptomsTHC co-useTHC useTestingTetrahydrocannabinol co-useTetrahydrocannabinol useTherapeuticTimeTranslationsUniversitiesWithdrawalWithdrawal SymptomWorkabuse liabilityabuse potentialanandamideaqueousarachidonoyl ethanolamidearachidonoylethanolamidearachidonylethanolamidebehavior studybehavioral studycannabimimeticscannabinergiccannabinoid receptor 1cannabinoid receptor type 1cannabinoid type 1cannabinoidergiccannabis usecannabis use disordercannabis withdrawalchemical informaticscheminformaticsclinical applicabilityclinical applicationcommercializationdesigndesigningdevelopmentaldrug developmentdrug discoverydrug discriminationdrug synthesisdrug/agenteCB systemendocannabinoid systemendogenous cannabinoid systemfatty acid amide hydrolaseheavy metal Pbheavy metal leadimprovedin vivoin vivo evaluationin vivo testinginhibitormarihuanamarijuana usemarijuana use and disordermarijuana use disordermedication therapy managementmonoacylglycerol lipase inhibitormultidisciplinarynatural hypothermianew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynon-human primatenonhuman primatenovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approacholeamide hydrolaseparentpharmaceuticalpharmacologicphase 2 studyphase II protocolphase II studypre-clinical trialpreclinical trialprofessorresponsescale upside effecttranslation
Applications closed.
Description preview
OTHER PROJECT INFORMATION – Unit 7 – Project Summary/Abstract
Abstract
This project addresses the growing need for medications for cannabis use disorder (CUD) which, in the
absence of approved medications, is a major focus of NIDA’s mission. Currently available cannabinergic-based
treatments for CUD include the directly acting CB1 agonists, e.g.,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click